At the time of writing, CME Group Inc [CME] stock is trading at $285.98, up 0.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CME shares have gain 2.92% over the last week, with a monthly amount glided 6.74%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CME Group Inc [NASDAQ: CME] stock has seen the most recent analyst activity on April 08, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $301 for it. Previously, Raymond James upgraded its rating to Outperform on March 10, 2025, and kept the price target unchanged to $287. On January 06, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $250 on the stock. Redburn Atlantic downgraded its rating to a Neutral but stick to its price target of $244 on October 08, 2024. RBC Capital Mkts initiated its recommendation with a Sector Perform and recommended $235 as its price target on September 27, 2024. TD Cowen started tracking with a Hold rating for this stock on September 26, 2024, and assigned it a price target of $221. In a note dated September 03, 2024, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $212 to $177.
For the past year, the stock price of CME Group Inc fluctuated between $186.08 and $286.48. Currently, Wall Street analysts expect the stock to reach $287 within the next 12 months. CME Group Inc [NASDAQ: CME] shares were valued at $285.98 at the most recent close of the market. An investor can expect a potential return of 0.36% based on the average CME price forecast.
Analyzing the CME fundamentals
According to CME Group Inc [NASDAQ:CME], the company’s sales were 6.28B for trailing twelve months, which represents an 10.38% jump. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at 0.65%, Pretax Profit Margin comes in at 0.74%, and Net Profit Margin reading is 0.57%. To continue investigating profitability, this company’s Return on Assets is posted at 0.02, Equity is 0.13 and Total Capital is 0.11. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 284.30 points at the first support level, and at 282.63 for the second support level. However, for the 1st resistance point, the stock is sitting at 287.35, and for the 2nd resistance point, it is at 288.73.
Ratios To Look Out For
Considering the valuation of this stock, the price to sales ratio is 16.40, the price to book ratio is 3.81 and price to earnings (TTM) ratio is 28.75.
Transactions by insiders
Recent insider trading involved Kaye Daniel G, Director, that happened on May 22 ’25 when 500.0 shares were sold. Director, Kaye Daniel G completed a deal on May 22 ’25 to buy 500.0 shares. Meanwhile, Sr MD General Counsel Marcus Jonathan L sold 390.0 shares on May 20 ’25.
